secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2026-07-09T10:08:49+00:00
Accession:  0001213900-26-076526
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences regains Nasdaq compliance; subject to one-year monitor
--------------------------------------------------------------------------

- Nasdaq notified ENDRA on July 8, 2026 that it regained compliance with the $2.5M Minimum Stockholders' Equity Requirement.
- Company had been below requirement; requested hearing on April 27, 2026, hearing held May 28, 2026.
- Subject to Discretionary Panel Monitor for one year from July 1, 2026.
- If non-compliant again during monitor period, no cure period; immediate delisting process begins.
- Company can request a new hearing if a delisting determination is issued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026076526/0001213900-26-076526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026076526/ea0297455-8k_endra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-076526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer